文献速递炎症性肠病

乌司奴单抗治疗克罗恩病后早期超声应答与进行性透壁缓解

Early Ultrasound Response and Progressive Transmural Remission After Treatment With Ustekinumab in Crohn's Disease.
PubMed 文献 · Clin Gastroenterol Hepatol · 2022-07-14

STARDUST试验的子研究采用肠道超声评估乌司奴单抗对中重度克罗恩病透壁炎症的影响。77例患者中,第4周即可判定超声应答并持续改善至第48周,第48周超声应答率和透壁缓解率分别为46.3%和24.1%,结肠及生物制剂初治患者应答更明显。

要点

  • 乌司奴单抗治疗克罗恩病第4周即可通过肠道超声判定应答,并持续改善至第48周。
  • 第48周超声应答率46.3%,透壁缓解率24.1%。
  • 第4周无超声应答与第48周无内镜应答相关,阴性预测值73%。

核心结论

  • 乌司奴单抗治疗的克罗恩病患者至第48周实现进行性超声应答(46.3%)和透壁缓解(24.1%),结肠及生物制剂初治患者应答更明显。

研究设计与样本

  • STARDUST为国际、多中心、3b期、干预性、随机对照试验,比较达标治疗与标准治疗策略。
  • 本子研究纳入77例接受乌司奴单抗治疗的中重度克罗恩病成人患者,以基线肠道超声显示最受累肠段进行分析。
  • 关键超声终点包括超声应答、透壁缓解、肠壁厚度、血流、肠壁分层和炎性脂肪,均采用中心判读且对参数设盲。

主要发现

  • 治疗开始后第4周即可判定超声应答,并持续改善至第48周。
  • 第48周超声应答率为46.3%,透壁缓解率为24.1%。
  • 超声应答、透壁缓解、肠壁厚度和血流正常化率在结肠及生物制剂初治患者中更明显。
  • 第4周超声应答与第48周整体内镜应答及粪便钙卫蛋白/完整生物标志物结局之间的一致性为一般至中等(κ=0.21-0.51)。
  • 内镜与超声在判定回肠末端为最受累肠段方面的基线一致率>90%;第4周无超声应答与第48周无内镜应答(基于简化克罗恩病内镜评分回肠末端子评分)相关,阴性预测值为73%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: In this STARDUST substudy, the effect of ustekinumab on transmural bowel inflammation was assessed in adults with moderate-to-severe Crohn's disease (CD) by using intestinal ultrasound (IUS), a noninvasive imaging procedure. METHODS: STARDUST was an international, multicenter, phase 3b, interventional, randomized controlled trial specifically designed to compare treat-to-target and standard-of-care treatment strategies in ustekinumab-treated CD patients. In this substudy, the most affected bowel segment at baseline by IUS was used for all analyses. Key IUS endpoints (centrally read, parameter-blinded) were IUS response, transmural remission, bowel wall thickness (BWT), blood flow, bowel wall stratification, and inflammatory fat. RESULTS: Seventy-seven patients were evaluated. IUS response could be determined 4 weeks after treatment initiation, with progressive improvement through week 48. IUS response and transmural remission rates at week 48 were 46.3% and 24.1%, respectively. IUS response, transmural remission, BWT, and blood flow normalization rates were more pronounced in the colon and biologic-naive patients. Fair/moderate reliability (κ = 0.21-0.51) was observed between week 4 IUS response and week 48 overall endoscopic response and fecal calprotectin/complete biomarker outcomes. Endoscopy and IUS baseline agreement was >90% in determining the terminal ileum as the most affected bowel segment. IUS response absence at week 4 was associated with no endoscopic response (based on the simplified endoscopic score for Crohn's disease terminal ileum subscore) at week 48 (negative predictive value = 73%). CONCLUSIONS: In this first international, multicenter, interventional study, IUS showed that ustekinumab-treated CD patients achieved progressive IUS response (46.3%) and transmural remission (24.1%) through week 48, with a more robust response in the colon and biologic-naive patients. CLINICALTRIALS: gov number: NCT03107793.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Kucharzik T, Wilkens R, D'Agostino MA, et al. Early Ultrasound Response and Progressive Transmural Remission After Treatment With Ustekinumab in Crohn's Disease. Clin Gastroenterol Hepatol. 2022. PMID: 35842121. doi:10.1016/j.cgh.2022.05.055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。